RUBY-I, cohort 2

RUBY-I Study, cohort 2: ombitasvir/paritaprevir/ritonavir + dasabuvir ± RBV for HCV genotype 1 with renal impairment

Vierling JM. AASLD 2016, Abs. 886

Anti-HCV
Paritaprevir/ritonavir
Ombitasvir
Dasabuvir
Ribavirin
Genotype
1a
1b
Treatment history
Naive
IFN-Experienced
Cirrhosis
Yes
No
Special population
Chronic Kidney disease

DOWNLOAD THIS SLIDE KIT

BROWSE SLIDES

Design


** Liver biopsy ( Metavir = F3, Ishak score = 4) or F ibroscan < 12.5 kPa or FibroTest = 0.72 + APRI = 2

Treatment regimens

  • Co-formulated ombitasvir (OBV)/ paritaprevir (PTV)/ rironavir (r): 25/150/100 mg qd = 2 tablets
  • Dasabuvir (DSV): 250 mg bid ; RBV 200 mg qd (genotype 1a)

Objective

  • SVR12, (HCV RNA < 25 IU/ml) by intent-to-treat with 2-sided 95% CI

Baseline characteristics


* eGFR 15- 30 ml/min/1.73 m² ; ** eGFR < 15 ml/min/1.73 m²

SRV12, %


* on - treatment breakthrough (non compliance , stopped taking all study drugs on D73 of treatment)
** discontinuation of study drug at D6 due to an adverse event (volvulus) not related to study drug

Adverse events and laboratory abnormalities

Summary

  • OBV/PTV/r + DSV ± RBV resulted in an SVR12 rate of 96 % in patients with CKD stages 4 or 5 in cohort 2 of the RUBY-I study
  • The regimen was generally well tolerated for this group of patients with severe underlying comorbidities, with
    • 1 possibly DAA-related serious adverse event of diarrhea
    • and 1 discontinuation due to an adverse event unrelated to treatment
  • A large proportion of patients on RBV required RBV dose modification for anemia
  • Most adverse events were mild or moderate in severity
  • These results of efficacy and safety support the use of this regimen in patients with advanced renal disease, for whom treatment options are limited